Neuromuscular BlockadeNCT07478120
Muscle and Fat Mass in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose
An observational study of Neuromuscular Blockade and Neuromuscular Blockade Monitoring, run by Seoul National University Bundang Hospital at 1 site in South Korea.
Trial summary
Deep neuromuscular blockade has benefits in various surgical procedures and reduces postoperative pain. While neuromuscular blockade dosages are often based on the patient's actual body weight, body composition can vary significantly depending on age, gender, and individual exercise levels. Read more about this study
- Who is it for?
- Ages 19 to 85 years
- Conditions the study is for
- Neuromuscular Blockade, Neuromuscular Blockade Monitoring
- What is being tested?
- Neuromuscular block
- How many people
- 31 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jan 2021to 1 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for elective gynecologic surgery under general anesthesia
Who may be able to join
- American Society of Anesthesiologists physical class (ASA class) 1-3
- Patients scheduled for elective gynecologic surgery under general anesthesia
- Patients undergoing abdominal computed tomography for routine preoperative preparation
Who cannot join
- Pregnant women
- Decreased renal function (GFR<60mL/min/1.73m2).
- Patients taking drugs that affect deep neuromuscular blockade
- Patients with a history of neuromuscular and muscle disorders
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Seoul National University Bundang Hospital
Gyeonggi-do, Sungnamsi, 13620
About this study
Official title: Relationship Between Muscle and Fat Mass Using Deep-learning Approach in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose Required for Maintaining Deep Neuromuscular Blockade in Patients Undergoing Gynecological Surgery
Deep neuromuscular blockade has benefits in various surgical procedures and reduces postoperative pain. While neuromuscular blockade dosages are often based on the patient's actual body weight, body composition can vary significantly depending on age, gender, and individual exercise levels. Therefore, uniformly estimating neuromuscular blockade dosages based on actual body weight can result in under- or over-administered neuromuscular blocking agents. Calculating neuromuscular blockade dosage based on actual body weight can be inaccurate, but it remains due to the difficulty of accurately quantifying human muscle and fat mass. Recent advances in image analysis techniques utilizing artificial intelligence models have led to the development of methods for quantifying muscle and fat mass from computed tomography (CT). Theoretically, a higher neuromuscular blockade dosage should be required as the muscle mass increases. This study aims to analyze the relationship between neuromuscular blocking agent dosage, onset time, profound blockade time, and recovery time, and muscle mass and fat mass calculated from preoperative CT scans.
- Being tested
- Neuromuscular block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromuscular blockOther
Neuromuscular blockade monitoring
What is being measured
The primary outcome is the main question the study is designed to answer.
muscle and fat mass
subject's muscle and fat mass from preoperative computed tomography images.
Measured: intraoperative period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Jan 2021
- Primary completion28 Feb 2021
- Study completion1 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuromuscular BlockadeStudies of the same condition, open and under way.
- More trials run by Seoul National University Bundang HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Park InSun, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07478120
- Sponsor's protocol ID
- B-2604-1036-102
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relationship Between Muscle and Fat Mass Using Deep-learning Approach in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose Required for Maintaining Deep Neuromuscular Blockade in Patients Undergoing Gynecological Surgery
- ClinicalTrials.gov ID
- NCT07478120
- Acronym / sponsor ID
- B-2604-1036-102
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- Seoul National University Bundang HospitalUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 28 Feb 2021 (actual)
- Study completion
- 1 Mar 2026 (actual)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Deep neuromuscular blockade has benefits in various surgical procedures and reduces postoperative pain. While neuromuscular blockade dosages are often based on the patient's actual body weight, body composition can vary significantly depending on age, gender, and individual exercise levels. Therefore, uniformly estimating neuromuscular blockade dosages based on actual body weight can result in under- or over-administered neuromuscular blocking agents. Calculating neuromuscular blockade dosage based on actual body weight can be inaccurate, but it remains due to the difficulty of accurately quantifying human muscle and fat mass. Recent advances in image analysis techniques utilizing artificial intelligence models have led to the development of methods for quantifying muscle and fat mass from computed tomography (CT). Theoretically, a higher neuromuscular blockade dosage should be required as the muscle mass increases. This study aims to analyze the relationship between neuromuscular blocking agent dosage, onset time, profound blockade time, and recovery time, and muscle mass and fat mass calculated from preoperative CT scans.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 19 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for elective gynecologic surgery under general anesthesia
Key inclusion criteria (3 listed)
- American Society of Anesthesiologists physical class (ASA class) 1-3
- Patients scheduled for elective gynecologic surgery under general anesthesia
- Patients undergoing abdominal computed tomography for routine preoperative preparation
Key exclusion criteria (4 listed)
- Pregnant women
- Decreased renal function (GFR<60mL/min/1.73m2).
- Patients taking drugs that affect deep neuromuscular blockade
- Patients with a history of neuromuscular and muscle disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromuscular blockNeuromuscular blockade monitoring | Other | – |
Primary outcome
muscle and fat mass
Time frame: intraoperative period
subject's muscle and fat mass from preoperative computed tomography images.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Neuromuscular Blockade
Active, not recruiting
Efficacy of Laparoscopic-Assisted TAP Block in Laparoscopic Appendectomy
Appendectomy, Laparoscopic, Blockades Neuromuscular
Not yet recruitingObservational study
Diaphragm Ultrasound and Neuromuscular Monitoring for Predicting Early Respiratory Events After Extubation
Residual Neuromuscular Blockade, Diaphragm Dysfunction
Recruiting
Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
Generalized Anxiety Disorder (GAD)
Not yet recruiting
Comparative Effects Of Exercises Targeting Upper Trapezius In Patients With Non Specific Neck Pain
Non Specific Neck Pain
RecruitingObservational study
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
Muscle Relaxants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuromuscular Blockade and Neuromuscular Blockade Monitoring, run by Seoul National University Bundang Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
muscle and fat mass (time frame: intraoperative period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.